LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Fedratinib | 10.0 | uM | LJP5 | 2 | L01 | 72 | hr | 2543 | 1751 | 5578 | 0.3139 | -0.2611 |
| SK-BR-3 | Fedratinib | 10.0 | uM | LJP5 | 3 | L01 | 72 | hr | 2543 | 1650 | 5578 | 0.2958 | -0.2944 |
| SK-BR-3 | TGX221 | 10.0 | uM | LJP5 | 1 | H19 | 72 | hr | 2543 | 5199 | 5578 | 0.9319 | 0.8749 |
| SK-BR-3 | TGX221 | 10.0 | uM | LJP5 | 2 | H19 | 72 | hr | 2543 | 5738 | 5578 | 1.0286 | 1.0525 |
| SK-BR-3 | TGX221 | 10.0 | uM | LJP5 | 3 | H19 | 72 | hr | 2543 | 5541 | 5578 | 0.9933 | 0.9876 |
| SK-BR-3 | Torin1 | 10.0 | uM | LJP6 | 1 | O13 | 72 | hr | 2543 | 1443 | 5578 | 0.2587 | -0.3626 |
| SK-BR-3 | Torin1 | 10.0 | uM | LJP6 | 2 | O13 | 72 | hr | 2543 | 1369 | 5578 | 0.2454 | -0.3869 |
| SK-BR-3 | Torin1 | 10.0 | uM | LJP6 | 3 | O13 | 72 | hr | 2543 | 1431 | 5578 | 0.2565 | -0.3665 |
| SK-BR-3 | Torin2 | 10.0 | uM | LJP5 | 1 | I19 | 72 | hr | 2543 | 1081 | 5578 | 0.1938 | -0.4818 |
| SK-BR-3 | Torin2 | 10.0 | uM | LJP5 | 2 | I19 | 72 | hr | 2543 | 1112 | 5578 | 0.1993 | -0.4716 |
| SK-BR-3 | Torin2 | 10.0 | uM | LJP5 | 3 | I19 | 72 | hr | 2543 | 1143 | 5578 | 0.2049 | -0.4614 |
| SK-BR-3 | Tozasertib | 10.0 | uM | LJP5 | 1 | B13 | 72 | hr | 2543 | 2103 | 5578 | 0.3770 | -0.1451 |
| SK-BR-3 | Tozasertib | 10.0 | uM | LJP5 | 2 | B13 | 72 | hr | 2543 | 2184 | 5578 | 0.3915 | -0.1184 |
| SK-BR-3 | Tozasertib | 10.0 | uM | LJP5 | 3 | B13 | 72 | hr | 2543 | 2217 | 5578 | 0.3974 | -0.1076 |
| SK-BR-3 | Trametinib | 10.0 | uM | LJP5 | 1 | P19 | 72 | hr | 2543 | 4189 | 5578 | 0.7509 | 0.5422 |
| SK-BR-3 | Trametinib | 10.0 | uM | LJP5 | 2 | P19 | 72 | hr | 2543 | 4297 | 5578 | 0.7703 | 0.5777 |
| SK-BR-3 | Trametinib | 10.0 | uM | LJP5 | 3 | P19 | 72 | hr | 2543 | 4663 | 5578 | 0.8359 | 0.6983 |
| SK-BR-3 | TWS119 | 10.0 | uM | LJP5 | 1 | M01 | 72 | hr | 2543 | 1300 | 5578 | 0.2330 | -0.4097 |
| SK-BR-3 | TWS119 | 10.0 | uM | LJP5 | 2 | M01 | 72 | hr | 2543 | 901 | 5578 | 0.1615 | -0.5411 |
| SK-BR-3 | TWS119 | 10.0 | uM | LJP5 | 3 | M01 | 72 | hr | 2543 | 1240 | 5578 | 0.2223 | -0.4295 |
| SK-BR-3 | Vemurafenib | 10.0 | uM | LJP5 | 1 | C13 | 72 | hr | 2543 | 5119 | 5578 | 0.9176 | 0.8486 |
| SK-BR-3 | Vemurafenib | 10.0 | uM | LJP5 | 2 | C13 | 72 | hr | 2543 | 5469 | 5578 | 0.9803 | 0.9639 |
| SK-BR-3 | Vemurafenib | 10.0 | uM | LJP5 | 3 | C13 | 72 | hr | 2543 | 4988 | 5578 | 0.8941 | 0.8054 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP5 | 1 | G13 | 72 | hr | 2543 | 1349 | 5578 | 0.2418 | -0.3935 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP5 | 2 | G13 | 72 | hr | 2543 | 1417 | 5578 | 0.2540 | -0.3711 |